Next Article in Journal
Desmoid Tumors in Pregnant and Postpartum Women
Previous Article in Journal
Does Secondary Inflammatory Breast Cancer Represent Post-Surgical Metastatic Disease?
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(1), 165-183; doi:10.3390/cancers4010165

Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan

Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan
*
Author to whom correspondence should be addressed.
Received: 16 January 2012 / Revised: 8 February 2012 / Accepted: 16 February 2012 / Published: 21 February 2012
View Full-Text   |   Download PDF [223 KB, uploaded 21 February 2012]

Abstract

Transcatheter methods such as transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) have an important role in the treatment for advanced hepatocellular carcinoma (HCC). Recently, sorafenib, an inhibitor of tyrosine kinases, has been found to obtain survival benefits in patients with HCC, leading to major advances in the treatment of advanced HCC. However, it is associated with a low tumor response rate, minimal survival advantage, and high rates of adverse events. On the other hand, high rates of objective treatment response with HAIC for advanced HCC have been reported, although convincing evidence of it contributing to overall survival in HAIC has been lacking. In Japan, HAIC still tends to be the preferred method for the treatment of advanced HCC, even in patients with poor liver function. However, the choice of chemotherapeutic agents in TACE/HAIC for HCC varies between institutions. In this review, based on studies reported to date in the literature, we refer to current knowledge regarding the chemotherapeutic agents used for TACE/HAIC for HCC in Japan and consider the future perspectives for HAIC for this cancer.
Keywords: advanced hepatocellular carcinoma; chemotherapy; hepatic arterial infusion chemotherapy; sorafenib; response rate advanced hepatocellular carcinoma; chemotherapy; hepatic arterial infusion chemotherapy; sorafenib; response rate
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nishikawa, H.; Osaki, Y.; Kita, R.; Kimura, T. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan. Cancers 2012, 4, 165-183.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top